Optimize Pseudomonas Eradication in Children

OPTIMIZing ­Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial (OPTIMIZE-IP-12)     

Purpose An eradication of initial pseudomonas in children with standard of care TOBI and azithromycin or placebo.

Study Status: Open to enrollment, Physician discretion for inclusion

Sponsor: NHLBI (National Heart Lung and Blood Institute)

 

Principal Investigator: Cori Daines, MD

 

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Study Status: 
Ongoing